TheraRadar
← Back
Data updated: Jun 28, 2026

BIOFRONTERA

Pharma
OncologyDermatology Execution: Excellent

BIOFRONTERA is a pharmaceutical company focused on Oncology, Dermatology. Key products include AMELUZ.

2000
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

BIOFRONTERA at a Glance

  • Strong track record with 100% execution quality across 5 trials
  • Fast trial execution (17 months median completion)

BIOFRONTERA's Key Drugs

BIOFRONTERA's core commercial portfolio centers on AMELUZ, spanning Oncology and Dermatology — its most strategically important drugs approved in the last 15 years.

AMELUZ
Dermatology

Actinic Keratosis

protoporphyrin IX Approved 2016

BIOFRONTERA's Recent FDA Approvals

New NDA/BLA approvals for BIOFRONTERA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BIOFRONTERA's Therapeutic Areas

BIOFRONTERA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 80%
0 drugs Phase 3: 2
Dermatology 20%
0 drugs Phase 2: 1

BIOFRONTERA's Top Competitors

BIOFRONTERA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Dermatology
Baxter specialty
Oncology, Dermatology
Eli Lilly big-pharma
Oncology, Dermatology
Bayer big-pharma
Oncology, Dermatology
KING PHARMS big-pharma
Oncology, Dermatology

BIOFRONTERA Pipeline Snapshot

BIOFRONTERA has 3 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 0 Phase 1.

2
Phase 3
1
Phase 2
0
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q3 2025
—
Actinic Keratoses
Completed · awaiting NCT05662202

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • AMELUZ leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/3 completed
  • • Speed: 17 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges